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Abstract
Tetraspanins are small transmembrane proteins, found in allBackground: 
higher eukaryotes, that compartmentalize cellular membranes through
interactions with partner proteins. CD81 is a prototypical tetraspanin and
contributes to numerous physiological and pathological processes, including
acting as a critical entry receptor for hepatitis C virus (HCV).
Antibody engagement of tetraspanins can induce a variety of effects, including
actin cytoskeletal rearrangements, activation of MAPK-ERK signaling and cell
migration. However, the epitope specificity of most anti-tetraspanin antibodies
is not known, limiting mechanistic interpretation of these studies.
We generated a panel of monoclonal antibodies (mAbs) specific forMethods: 
CD81 second extracellular domain (EC2) and performed detailed epitope
mapping with a panel of CD81 mutants. All mAbs were screened for their ability
to inhibit HCV infection and E2-CD81 association. Nanoscale distribution of cell
surface CD81 was investigated by scanning electron microscopy.
 The antibodies were classified in two epitope groups targetingResults:
opposing sides of EC2. We observed a wide range of anti-HCV potencies that
were independent of their epitope grouping, but associated with their relative
affinity for cell-surface expressed CD81. Scanning electron microscopy
identified at least two populations of CD81; monodisperse and higher-order
assemblies, consistent with tetraspanin-enriched microdomains.
These novel antibodies provide well-characterised tools toConclusions: 
investigate CD81 function, including HCV entry, and have the potential to
provide insights into tetraspanin biology in general.
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Introduction
The tetraspanin superfamily of small integral membrane pro-
teins are characterised by their four transmembrane domains 
linked by intracellular and extracellular loops containing highly- 
conserved cysteine residues. They are present in higher eukaryo-
tes at both the cell surface and endosomal membranes, where 
they exert a variety of functions, including regulating signal-
ling, facilitating protein trafficking and influencing membrane 
fusion. Tetraspanins are largely without cognate ligands and are 
thought to function through heterotypic interactions with other 
membrane proteins, which they organise into so-called tetraspanin 
enriched microdomains or tetraspanin webs. As such, tetraspanins 
play an essential role in the compartmentalisation of cellular 
membranes1–3.
CD81, like many other tetraspanins, interacts with diverse 
partners in a cell type dependent manner to regulate a variety of 
processes, for example: CD81 association with CD19 regulates 
B cell signalling4–6; interactions with CD3 and ICAM-1 regulate 
the integrity of the immune synapse during T-cell activation7; and, 
in concert with another tetraspanin CD9, CD81 plays a role in 
sperm-egg fusion, making it important for mammalian fertility8. 
Notably, CD81 is co-opted during the life cycle of diverse 
human pathogens: it is involved in hepatitis C virus (HCV) and 
Plasmodium sporozoite9–11 invasion of hepatocytes, and also 
contributes to the assembly and budding of human immunodefi-
ciency virus and influenza A virus12–14.
As a consequence of its involvement in these physiological 
and pathological processes, CD81 has become one of the most 
intensely-studied tetraspanins. It is, therefore, unsurprising that 
it is the first tetraspanin for which a complete crystal structure is 
available15. Zimmerman et al. reported that the four transmem-
brane domains of CD81 form a cone shape containing an internal 
cavity. The structure revealed a single cholesterol molecule sat in 
this cavity, stabilised by a hydrogen bond to a closely opposed 
transmembrane domain. The second extracellular loop (EC2) 
sits across the transmembrane cone in a closed conforma-
tion. However, molecular dynamic simulations suggest that if 
cholesterol is removed from the central cavity of CD81, the EC2 
has a propensity to switch to an open conformation; this implies 
that cholesterol may act as an allosteric regulator of CD81 con-
formation and function. It is possible that the conformation 
revealed in this crystal structure and the apparent cholesterol 
binding may be an artefact of lipid cubic phase crystallization15. 
However, there is a well-established literature on the role of 
cholesterol in tetraspanin biology and more specifically on 
CD81-dependent cell invasion by HCV and Plasmodium 
sporozoites16–19.
Our principal interest in CD81 is in the context of HCV entry. 
Direct interaction between the major viral glycoprotein E2 and 
CD81 EC2 is essential for HCV invasion of hepatocytes9,20–22. 
CD81 plays a role in the assembly of higher-order entry recep-
tor complexes that direct HCV particles for clathrin-mediated 
endocytosis23–25 and fusion in the early endosome26.
In the present study, we generated a panel of murine monoclonal 
antibodies (mAbs) against full-length CD81 to further examine 
these processes. Although a number of CD81 mAbs are available, 
little or no epitope mapping data exists27–31. We used linear pep-
tide arrays and defined EC2 mutants to epitope map the mAbs and 
assessed their ability to inhibit or neutralize HCV infection. We 
observed a significant correlation between mAb neutralizing activ-
ity and affinity for CD81 expressed in the context of mammalian 
cells that was independent of epitope reactivity. Finally, we selected 
two high-affinity mAbs to examine the nanoscale distribution of 
CD81 by immunogold scanning electron microscopy (SEM); these 
data suggest that at least two populations of cell surface CD81 exist 
with distinct spatial distributions. These mAbs provide a panel of 
well-characterised tools to investigate the basic biology and func-
tion of CD81.
Methods
Cell lines, antibodies, and reagents
Huh-7.5 cells (provided by Charles Rice, The Rockefeller 
University, New York, NY)32, Huh-7 KO CD81 (provided by 
Yoshiharu Matsuura, Osaka University)33, Parental HepG2 and 
those transduced to stably express human or mouse CD8134, and 
293T cells (American Type Culture Collection, ATCC) were 
propagated in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% foetal bovine serum and 1% nonessen-
tial amino acids (Thermo Fisher, USA). All cells were grown in a 
humidified atmosphere at 37°C in 5% CO2. Anti-NS5A mAb 9E10 
was provided by C. Rice, (Rockefeller University). Rat anti-E2 
antibodies 6/1a, 7/59, and 7/16 have been previously described35. 
Secondary goat anti-mouse immunoglobulin G (IgG) antibodies, 
labelled with Alexa Fluor 488 (A-11001) and Alexa Fluor 
647 (A-21235), was obtained from Thermo Fisher, HRP- 
conjugated sheep anti-mouse IgG (NA931) and goat anti-rat 
(NA935) was obtained from GE Healthcare.
Generation of CD81 antibodies
Balb/c mice were immunised with recombinant human CD81 
(CD81FL), purified by detergent extraction from a membrane 
fraction of Pichia pastoris as previously described36. Hybridomas 
were generated by a method based on that reported by Galfre and 
Milstein37. NS0 immortal fusion partner cells were fused with 
splenocytes by PEG (StemCell Technologies, Canada). Hybri-
doma supernatants were screened for reactivity with CD81FL and a 
truncated form of CD81 comprising EC2 fused to maltose binding 
protein (MBP-CD81EC2)38,39.
Assessing antibody interaction with CD81 by ELISA
Immulon 2HB plates (Thermo Fisher, USA) were coated with 
PBS containing either 5µg/mL recombinant CD81FL or a panel 
of MBP-CD81EC2 mutant constructs, as previously described38,39. 
Alternatively, plates were coated with P. pastoris protoplast mem-
branes containing CD8136. Overlapping peptides (25 aa, overlap 
of 10) corresponding to the entire sequence of CD81 were bound 
to plates overnight (25 µg/mL in a 50mM carbonate-bicarbonate 
buffer, pH9.6)31. After washing and blocking with 5% BSA/PBS 
for 1h, the anti-CD81 mAbs were added at 2 µg/mL in PBS 
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containing 5% BSA and 0.05% Tween-20. After a 2h incubation at 
room temperature, the plates were washed and bound antibody was 
detected with 1/1000 anti-mouse Ig-HRP, 1h incubation at room 
temperature. After washing, HRP-conjugates were detected colori-
metrically with a TMB substrate solution and absorbance read at 
450nm in accordance with the manufacturer’s instructions (BioFX, 
USA).
Genesis of protoplasts expressing CD81
Recombinant CD81 protein was produced in P. pastoris X33 cells 
(Thermo Fisher) under the control of the AOX1 promoter using the 
pPICZB vector (Thermo Fisher), as previously described36,40,41. To 
generate protoplasts, a mid-logarithmic phase aliquot of P. pastoris 
X33 cells was re-suspended in a phosphate buffer (50mM KH2PO4, 
40 mM β-mercaptoethanol, pH 7.2) and incubated for 30 min at 
30°C. The cell suspension was diluted 1:1 in phosphate buffer con-
taining 2.4 M sorbitol and Zymolyase 20T at a final concentration 
of 1 mg/mL and incubated for 90 min at 30°C. After harvesting, the 
protoplasts were washed once in phosphate buffer and resuspended 
in storage buffer 250mM KCl, 10mM CaCl2, 5mM MgCl2, 5mM 
MES, pH 7.2 supplemented with 1% glucose.
Assessing anti-CD81 mAb binding to cells by flow 
cytometry
Anti-CD81 were incubated at increasing concentrations with 
Huh-7.5, HepG2, HepG2-CD81 cells at 37°C for 1h, in the pres-
ence of 0.01% sodium azide to prevent antibody internalization. 
Cells were washed 3 times in PBS and bound mAbs detected with 
1/1000 Alexa Fluor 488 conjugated anti-mouse antibody, 1h at 
37°C. After 3 PBS washes, cells were fixed with 1% formaldehyde 
and the captured fluorescent antibody quantified by flow cytometry. 
To acquire data, voltages for the Alexa Fluor 488 channel were set 
using HepG2 cells, which do not express CD81, as a negative 
control. To analyse, intact singlet cells were gated using the forward 
and side scatter channels and their median fluorescence intensity 
in the green channel used to assess antibody binding. Analysis 
was performed using FlowJo v8.3 (Treestar, USA). Repre-
sentative histograms of fluorescence intensities are provided in 
Supplementary Figure 1.
Genesis of virus and neutralisation of infection
Cell culture proficient HCV (HCVcc) strain J6/JFH was generated 
as previously described21. Briefly, RNA was transcribed from lin-
earized full-length genomes and electroporated into Huh-7.5 cells. 
High-titre stocks were generated by passage of the virus in naïve 
Huh-7.5 cells42. Supernatants were collected at 72 and 96h post 
infection, pooled and stored at -80°C. To measure the neutraliz-
ing capacity of the anti-CD81 mAbs, Huh-7.5 cells were seeded at 
1.5x104 cells/cm2 and after 24h incubated with an increasing con-
centration of CD81 mAbs for 1h at 37°C, prior to infecting with 
HCVcc for 1h. Unbound virus or antibody was removed by washing 
and the media replaced with DMEM/3% FBS. After 48h, infected 
cells were detected after methanol fixation by staining for NS5A 
using the 100ng/ml 9E10 antibody, for 1 hour at room temperature; 
bound antibody was detected with 1/1000 Alexa Fluor 488 conju-
gated anti-mouse IgG, for 1 hour at room temperature, and NS5A 
expressing cells enumerated manually by fluorescence microscopy. 
mAb neutralization is defined as the percentage reduction in NS5A 
expressing cells compared to an irrelevant IgG. The concentration 
of mAb able to reduce the frequency of HCV NS5A expressing 
cells by 50% was calculated (IC50).
Immunogold SEM and analysis
1x105 HEK 293T were seeded onto 9mm glass coverslips and fixed 
after 48h in 2% EM grade formaldehyde/0.1% glutaraldehyde/
PBS. Samples were quenched with 2mg/ml NaBH4/PBS for 5 min 
and blocked in 1% BSA/PBS for 30 min. The fixed cells were 
incubated at room temperature for 1h with anti-CD81 mAbs 1s337 
or 2s20 at 2µg/ml in 1% BSA/PBS plus 0.1% BSA-c (Aurion, 
Netherlands), followed by 3 x 5 min PBS washes. Bound antibody 
was detected by incubation at room temperature for 1h with protein 
A conjugated to 10nm gold particles (Utrecht University Medical 
Center, Netherlands), diluted 1/60 in PBS + 1% BSA, followed by 
3 x 5 min PBS washes.
To prepare for SEM, the samples were sequentially post-fixed in 
1% glutaraldehyde, and 1% osmium/1.5% potassium ferrocyanide, 
and then dehydrated with serial incubation in 70, 90 and 100% 
ethanol. The samples were critically point dried, mounted for SEM 
and coated with carbon for 30 min. Samples were imaged on a Jeol 
7401 high resolution Field Emission Scanning Electron Micro-
scope (Jeol, Japan) at 40,000X magnification. To acquire images, 
the secondary electron channel was used to identify areas that had 
no topological features apparent, this mitigates the possibility of 
artifactual gold particle clustering due to underlying 3D structure. 
The distribution of gold particles was then acquired using the back-
scatter channel; this captures the composition of the sample and, 
provides maximum contrast between the cell surface and the gold 
particles. To quantify the images, the xy co-ordinates of each gold 
particle were extracted in ImageJ v2.0.0-rc-4343,44: first the spot 
enhancing filter was used to enhance gold particle contrast, then 
gold particles were identified automatically using the ParticlePicker 
plugin (The New Mexico SpatioTemporal Modeling Center), with 
each particle manually confirmed and corrected as necessary. The 
particle co-ordinates were then analysed using Ripley’s L function, 
implemented in Matlab vR2013a (MathWorks, USA). 
Fluorescence microscopy
Huh-7 CD81 KO cells were transduced with lentiviral vectors 
encoding human CD81, the transfer vector plasmid used for this can 
be found on Addgene. After 48h the transduced cells were seeded 
into 96 well plate at 1.5x104 cells/well, alongside untransduced 
control cells. 24h later the cells were fixed with 4% formaldehyde 
and blocked in 5% BSA/PBS for 1h. Anti-CD81 hybridoma 1s73, 
2s66 and 1s337 supernatants were diluted ¼ in 0.5% BSA/PBS and 
incubated with cells for 1h at room temperature, after washing with 
PBS, bound mAbs were detected with Alexa Fluor 647 conjugated 
anti-mouse antibody diluted 1/1000 for 1h at room temperature. 
At this stage 2 µg/mL DAPI was included to counterstain nuclear 
DNA. Samples were imaged using a Nikon Ti inverted microscope 
fitted with a motorized encoded stage. A 2.5 mm by 2.5 mm area of 
each well was acquired by image stitching using an ORCA Flash 
4 sCMOS camera (Hamamatsu, Japan), with 405 nm and 647 nm 
fluorescence illumination provided by a PE4000 LED (CoolLED, 
UK) unit through a multi-band excitation/emission filter cube 
(Semrock, USA).
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HCV E2-CD81 binding assay
GST-CD81EC234 was diluted in PBS at 5ug/ml and used to coat 
Immulon ELISA plates overnight at 4°C. Unbound protein was 
removed by 3x PBS washes and wells blocked with 5% BSA/PBS 
for 1h at room temperature. Plates were incubated with 1µg/ml 
anti-CD81 mAbs or irrelevant mouse Ig and a saturating amount 
of soluble HCV E2 diluted in binding buffer (5% BSA/ 20% sheep 
serum/ 0.05% Tween 20/PBS) for 4h at room temperature. After 
washing, bound HCV E2 was detected using rat anti-E2 antibod-
ies 6/1a, 7/59, and 7/16, each diluted 1:10 in binding buffer for 
1h at room temperature, followed by 1/1000 HRP-conjugated 
anti-rat IgG, 1h incubation at room temperature. After washing, 
HRP-conjugates were detected colorimetrically with a TMB sub-
strate solution and absorbance read at 450nm in accordance with 
the manufacturer’s instructions (BioFX, USA). Inhibition of 
HCV E2-CD81 association was determined relative to binding in 
the presence of an irrelevant mouse IgG34.
Results
Generation of anti-CD81 monoclonal antibodies
We previously reported the expression and purification of 
full-length human CD81 (hCD81FL) in Pichia pastoris36. 
Detergent-extracted CD81 was used to immunize mice and this 
elicited a polyclonal antibody response in all cases. Hybridomas 
were generated by PEG-mediated fusion of splenocytes with 
the NS0 cell line and the resulting antibodies screened for reac-
tivity with hCD81FL and a truncated form of CD81, compris-
ing the EC2 fused to maltose binding protein (MBP-CD81EC2)38. 
Thirty-two hybridomas bound hCD81FL and 14 were reactive with 
MBP-CD81EC2 (Table 1). All of the reactive hybridomas were sin-
gle cell cloned, isotyped and their reactivity for CD81 confirmed. 
To evaluate whether the mAbs recognise cell-surface CD81, we 
screened the panel for reactivity with HepG2 hepatoma cells that 
lack CD81 and with cells transduced to express human CD8134. 
All of the EC2-specific mAbs bound to HepG2-hCD81 cells with 
varying intensities, whereas the remaining non-EC2 mAbs showed 
negligible binding (Table 1). None of the mAbs exhibited bind-
ing to HepG2 cells expressing murine CD8134 by indirect immun-
ofluorescence microscopy, indicating good species specificity 
(data not visualised). The 18 non-EC2-specific mAbs bound to 
HepG2-hCD81 following fixation and permeabilization, suggest-
ing reactivity with intracellular or transmembrane domains (data 
not visualised). Representative flow cytometry histogram plots 
for mAb binding to Huh-7.5 cells are shown in Supplementary 
Figure 1, alongside fluorescence microscopy images of antibody 
reactivity for Huh-7 CRISPR Cas9 CD81 KO cells33 with and 
without CD81 addback, providing additional data on the specificity 
of these mAbs for CD81. Although not conclusive, these observa-
tions suggest that we failed to isolate mAbs targeting the smaller 
EC1 extracellular loop; notably, this region was not resolved 
in the recent crystal structure, presumably because it is structurally 
disordered15, which may explain its poor immunogenicity.
Epitope mapping anti-CD81 EC2 mAbs
The EC2-specific mAbs were screened for their ability to bind 
linear peptides covering the full length of the EC231. Five of the 
fourteen mAbs (2s20, 2s48, 2s63, 2s66 and 2s131) bound a 
peptide representing amino acids 173–192 (Figure 1A). Attempts 
Table 1. Generation of anti-CD81 monoclonal antibodies. A screen 
of candidate hybridomas identified thirty-two CD81 reactive 
clones, as summarised here. The first two columns display mAb 
reactivity with recombinant hCD81FL and MBP-CD81EC2. The latter 
columns display binding to parental HepG2 cells that lack CD81 
and those transduced to express exogenous CD81.
Clone ID
Reactivity with1 Binding to2
hCD81FL MBP-CD81EC2 HepG2 HepG2CD81
1 1s5 0.71 - - -
2 1s42 0.58 - - -
3 1s90 0.68 - - -
4 1s94 0.79 - - -
5 1s112 0.87 - - -
6 1s116 1.1 - - -
7 1s141 0.67 0.06 - -
8 1s204 0.79 - - -
9 1s346 0.21 - - -
10 2s1 1.16 - - -
11 2s4 0.92 - - -
12 2s22 0.89 - - -
13 2s25 1.16 - - -
14 2s84 0.98 - - -
15 2s107 0.64 - - -
16 2s113 0.32 - - -
17 2s116 1.09 - - -
18 2s136 0.77 - - -
19 1s73 0.25 0.76 - +
20 1s135 1.9 1.79 - +
21 1s201 2.67 2.15 - ++
22 1s262 0.33 0.89 - +
23 1s337 1.72 1.89 - +++
24 2s20 1.33 1.77 - +++
25 2s24 1.9 0.45 - +
26 2s48 2.33 2.1 - ++
27 2s63 1.53 2.01 - +
28 2s66 1.76 1.72 - ++
29 2s131 2.01 1.94 - ++
30 2s139 1.57 1.99 - ++
31 2s141 2.13 2.02 - +
32 2s155 2.7 2.06 - +
1 mAb (1 µg/mL) ELISA reactivity with hCD81FL and MBP-CD81EC2, where 
the data are expressed at optical density at 450nm.
2 mAb (1 µg/mL) binding to HepG2 and HepG2CD81 cells, where the data 
represent flow cytometry median fluorescence intensity (MFI) values: - no 
binding; + represents an MFI < 100; ++ represents an MFI 100 – 400 and 
+++ represents an MFI >400.
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Figure 1. Epitope grouping of anti-CD81 EC2 mAbs. The panel of CD81 EC2-specific antibodies were epitope mapped by measuring 
immunoreactivity to linear overlapping peptides covering EC2 and a panel of MBP-CD81EC2 constructs bearing defined point mutations. 
A. The antibody name, isotype and anti-HCV neutralizing activity are listed on the left. Reactivity against linear peptides is provided in the 
central column. The heat map displays reactivity against MBP-CD81EC2 mutants where the data are expressed relative to wild-type MBP-
CD81EC2. Red colouring indicates reduced binding, as shown in the legend. The antibodies were classified into three groups according to 
these combined data; this is shown on the right. B. Relevant domains and mutations mapped onto the CD81 crystal structure (PDB: 5TCX). 
The EC2 is shown in blue, whilst the transmembrane domains are grey. The region binding group I mAbs is depicted in orange, whereas the 
mutations that block group II mAbs are shown in red. C. The EC2 structure is shown in isolation. The leftmost image uses the same colour 
coding as above, the right hand images illustrate helices A–E, as indicated in the legend. The intermolecular disulphide bonds (disrupted by 
the C157S and C190R mutations) are shown in red. 1 Anti-HCV activity is expressed as the IC50 (µg/ml) against HCVcc strain J6/JFH infection. 
2 mAb (5 µg/mL) binding to overlapping EC2 peptides; reactivity was only observed for a peptide representing amino acids 173-192.
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to localise the binding site of the mAbs to shorter peptides cov-
ering this region were unsuccessful. To further investigate 
epitope specificity, we exploited a panel of MBP-CD81EC2 proteins 
bearing a variety of mutations that play a role in binding HCV 
E2 and that are reported to modulate CD81 conformation31,38,39. 
mAb binding was assessed by ELISA and the data expressed rela-
tive to reactivity against wild type MBP-CD81EC2, shown in the heat 
map in Figure 1A.
Mutation of cysteine residues necessary for intra-molecular di-
sulphide bonds prevented the binding of all mAbs, suggesting 
that ‘native’ folding of EC2 is necessary for the presentation of all 
epitopes. A collection of mutations around helix D and E of the 
EC2 (residues 176, 182, 184, 186) did not affect the binding of any 
mAbs, despite these residues being located within the linear peptide 
described above. We identified a constellation of mutations, within 
helices A, B and C of the EC2, that abolished the reactivity of a 
subset of mAbs (Figure 1A).
These data allowed us to classify the mAbs into three epitope 
groups: group I mAbs (2s20, 2s48, 2s63, 2s66 and 2s131) rec-
ognise a region centred around helix D of the EC2 (as identi-
fied by the peptide screen); group II mAbs (1s337, 1s262, 1s73, 
1s135, 1s201, 2s24, 2s141 and 2s155) recognise similar, likely 
discontinuous, epitopes across helices A, B and C, and can 
be subdivided into groups IIa and IIb based on their response to 
the MBP-CD81EC2 mutants; the specificity of 2s139 (designated 
a group III mAb) was not determined by either peptide screen or 
the panel of mutants. The residues that are important for 
group I and II mAb binding are annotated on full-length CD81 
(Figure 1B) and CD81 EC2 (Figure 1C) structures, where the 
location of these regions in relation to helices A–E and critical 
disulphide bonds within EC2 are shown.
Inhibition of HCV entry
HCV glycoprotein E2 binds directly to CD81 and, despite 
the absence of an E2-CD81 co-crystal structure, mutagenesis 
studies and negative stain electron microscopy have provided a 
reasonable understanding of this viral-receptor interaction. 
Current literature suggests that HCV E2 binding site for CD81 
is discontinuous and is focused on a putative receptor binding 
loop that contacts helix D of CD81 EC2, although helix C may also 
contribute to binding38,39,45–47.
Several reports suggest that anti-CD81 mAbs inhibit HCV infec-
tion by preventing this critical interaction27,28. We assessed the 
inhibitory activity of our anti-CD81 EC2 mAbs against HCVcc 
and determined the concentration of each mAb required to inhibit 
infection by 50% (IC50). Since group I mAbs target helix D, the 
main target for HCV E2 interactions, whereas group II antibodies 
appear to bind the opposing side of the EC2, we reasoned that the 
epitope groupings of the mAbs may define their neutralizing capac-
ity. Figure 2 shows the IC50 values for each mAb grouped accord-
ing to epitope specificity. Whilst the individual mAbs differ widely 
in their neutralizing activity (across a ~500-fold range), this did 
not correlate with epitope grouping. This suggests that any EC2-
specific mAb has the potential to perturb CD81 interaction with 
HCV. To examine this further, we assessed the ability of the mAbs 
to inhibit binding of a truncated soluble form of HCV E2 to CD81 
EC2 (Supplementary Figure 2). All of the mAbs displayed potent 
blocking of this interaction, but this did not correlate with epitope 
grouping or neutralizing activity, suggesting that in vitro measure-
ments of interactions between recombinant forms of HCV E2 and 
CD81 do not recapitulate the nuances of virus-receptor binding at 
the cell surface.
To further examine the correlates of mAb anti-viral activity, we 
assessed mAb binding to CD81 presented in three different con-
texts: i) recombinant full-length CD81 expressed and detergent 
purified from P. pastoris yeast, ii) membrane resident CD81 on the 
surface of P. pastoris protoplasts and iii) endogenous CD81 present 
in the plasma membrane of human hepatoma Huh-7.5 cells; this 
latter context can be considered the most physiologically-relevant 
setting. Figure 3 displays the relative binding affinities of the mAbs, 
in each context, plotted against anti-HCV neutralizing activity. 
Whilst all mAbs bind to detergent-purified CD81, there was 
Figure 2. Potency of anti-HCV activity does not correlate with epitope grouping. The antibodies were assessed for their ability to inhibit 
HCVcc J6/JFH infection of Huh-7.5 human hepatoma cells. The data is shown as the 50% inhibitory concentration (IC50) for each epitope 
group.
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Figure 3. Potency of HCV entry inhibition correlates with binding to Huh-7.5 cells. Each antibody was assessed for its ability to bind to 
CD81 presented in different contexts A. Recombinant full-length CD81, expressed in Pichia pastoris and detergent extracted. B. Recombinant 
full-length CD81 presented on the surface membrane of P. pastoris protoplasts C. Endogenous CD81 on the plasma membrane of Huh-7.5 
cells. mAb binding to purified CD81 (A.) and P. pastoris protoplasts (B.) was assessed by ELISA (optical density at 450nm), mAb binding 
Huh-7.5 cells (C.) was assessed by flow cytometry (median fluorescence intensity). In each case half-maximal binding values are displayed. 
Curve fitting was performed using the log-log line equation in GraphPad Prism 6.0, the goodness of fit (r2) and slope are provided for each fit. 
The outlying values boxed in C. were excluded from the analysis.
little variation in signal between them and consequently this met-
ric does not correlate with anti-HCV activity. A similar pattern 
was observed for mAb binding to membrane-resident CD81 on 
P. pastoris protoplasts, albeit with a modest trend towards correla-
tion. In contrast, the intensity of mAb binding to CD81 present on 
the surface of Huh-7.5 cells was predictive of anti-HCV activity 
(Figure 3C). Taken together, these data suggest that the strength 
of the intrinsic antibody-CD81 interaction is roughly equiva-
lent for each of the mAbs, as evidenced by the comparatively 
similar binding profiles for recombinant CD81 (Figure 3A & B). 
However, when in a physiologically-relevant membrane (i.e. Huh-
7.5 hepatoma cells), CD81 is displayed in a manner that alters 
epitope presentation, revealing nuances in mAb binding, which, in 
turn, determines the potency of anti-HCV activity.
Investigating the nanoscale distribution of CD81
Tetraspanins act as scaffolds to organise molecular events occur-
ring at cellular membranes. They exert this function by regulat-
ing the distribution of molecular partners across the membrane. 
However, this characteristic can be difficult to study: it involves 
relatively subtle changes to the architecture of nanoscale clusters 
of membrane proteins, is dynamic and is likely to be dependent 
on the local membrane context. As such, ultra high-resolution 
imaging techniques, such as electron microscopy (EM) or super-
resolution fluorescence microscopy, offer some of the best tools 
to study tetraspanin biology, as they can reveal the molecular 
distribution of tetraspanins and their partners in situ6,48,49. We were 
therefore interested to ascertain whether our anti-CD81 mAbs 
could reveal details of the nanoscale distribution of CD81.
Two mAbs, 2s20 (epitope group I) and 1s337 (group II), dis-
played high affinity for CD81 on the surface of mammalian cells 
(Figure 3C). We reasoned that these would perform well in micro-
scopy studies and used them to stain fixed cells for immunogold 
scanning EM. HEK 293T cells were chosen for these experiments 
as they express high levels of CD81 and have relatively flat plasma 
membranes, free of complex membrane folds that can compli-
cate the analysis of protein distribution. Notably, HEK 293T cells 
can be engineered to support HCV entry, via the introduction of 
claudin-142, demonstrating that CD81 is receptor active in this 
cellular context. Figure 4A displays representative electron 
micrographs of the cell surface of fixed HEK 293T cells; 
antibody-labelled CD81 was detected with protein A conju-
gated to 10nm gold particles, such that the distribution of gold 
particles mirrors that of CD81. Fields containing flat membrane 
without obvious three-dimensional membrane structures (e.g. 
ruffles or microvilli) were chosen to minimise artifactual 
clustering of gold particles.
mAb 2s20 appears to recognise two distinct populations of 
CD81: monodispersed CD81, represented by spatially-separated 
gold particles, and clustered CD81 that is arranged into higher-
order assemblies. Clustered CD81 appeared in both discrete 
tightly-packed assemblies and in linear arrangements, the latter of 
which may represent accumulation of CD81 on subtle topological 
features (Figure 4A). In contrast, only monodispersed CD81 was 
apparent in the 1s337 labelled cells, suggesting that this mAb 
does not bind the clustered population of CD81. However, there 
was a relatively high frequency of gold particle pairs, suggesting 
that 1s337 may detect lower order oligomers of CD81, such as 
dimers.
To quantify the apparent differences in mAb-labelled CD81, we 
used validated spatial statistics analysis tools. Ripley’s L func-
tion assesses whether the spatial organisation of a set of points, in 
this case gold particles, deviates from a random distribution over a 
range of length scales50–52. Analysis of a completely random data 
set generates a horizontal line, where the L function value is ~0 
irrespective of the length scale (Figure 4B). Deviation above or 
below this line indicates clustering or dispersal of points, respec-
tively. The Ripley’s L function for both mAbs indicates a non- 
random, clustered distribution of CD81 (Figure 4B). For mAb 
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Figure 4. Investigation of CD81 nanoscale organisation by immunogold scanning electron microscopy. Antibodies 2s20 and 1s337 
were used to assess the cell-surface distribution of CD81 on HEK 293T cells by immunogold SEM. A. Images display representative fields of 
antibody-stained cells. 2s20 staining revealed both monodisperse CD81 and CD81 organised into higher order assemblies; these included 
tightly packed clusters (black arrowheads) and linear arrangements (white arrowheads). 1s337 largely revealed monodispersed CD81, 
although there were also gold particle doublets (asterisks in inset images). Scale bars: 500nm (main images) and 100 nm (inset images). 
B. Spatial statistics analysis by Ripley’s L Function. The plot displays the calculated Ripley’s L Function values for 2s20 (n= 6 images) and 
1s337 (n=14) over a 100 nm radius. A simulated random point distribution gives a straight line, as expected. Both antibodies deviate from 
spatial randomness, indicating clustering. For 1s337 there is a distinct peak at short distances, consistent with the gold particle doublets. 
2s20 displays increasing L function values up to and beyond 100 nm, which is consistent with the higher order structures apparent in panel 
A. The dashed line indicates the smallest scale at which clustering can be assessed; this is limited by the size of the gold particles (10 nm).
2s20, the L-function increases with a gentle slope to reach a 
plateau at a relatively high value that extends beyond the X-axis; 
this indicates that 2s20-labelled CD81 exhibits clustering at length 
scales up to and beyond 100nm, consistent with the higher-order 
assemblies visible in Figure 4A. CD81 labelled with 1s337 gen-
erates a subtle curve away from randomness, with a modest peak 
at short length scales (~20nm), likely representing gold particle 
pairs, before dropping away at longer length scales, reflecting 
the largely monodispersed distribution of CD81. This statistical 
analysis is consistent with a model where at least two populations 
of CD81 co-exist at the plasma membrane, that are differentially 
recognised by the mAbs.
Discussion
There are a variety of pre-existing mAbs targeting CD8127–30; how-
ever, their binding specificities are unknown. Here we describe the 
generation of a panel of epitope-mapped anti-CD81 EC2 mAbs. 
The mAbs can be broadly divided in to two epitope groups: group 
I, which exhibit reactivity to linear EC2 peptides and likely rec-
ognise continuous epitope(s) focussed around helix D; and group 
II, which likely bind discontinuous epitope(s) containing elements 
of helixes A–C (Figure 1C). This classification may lead us to 
predict that group I antibodies are relatively insensitive to protein 
conformation, whereas group II antibodies only recognise natively-
folded EC2. However, mutational disruption of intramolecular 
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disulphide bonds blocked the binding of all mAbs, irrespective of 
epitope grouping (Figure 1A). Consistent with this, western blot 
analysis under reducing conditions (where disulphide bonds are 
broken) prevents the binding of all mAbs. Conversely, under non-
reducing conditions (where disulphide bonds are intact but the 
protein is denatured) all group I and many group II mAbs retain 
reactivity. As such we have been unable to classify the mAbs as 
having either linear or conformational epitopes; it is likely that all 
mAbs require presentation of their epitope in the correct context 
but many tolerate some degree of protein denaturation. Repre-
sentative western blots of group I and II mAbs under reducing and 
non-reducing conditions are provided in the OSF repository 
associated with this paper (see data hosting section).
It is important to note that whilst we classified the mAbs based 
on their apparent epitope specificity, we have not mapped the criti-
cal binding residues for any of the mAbs. For example, group I 
mAbs target epitope(s) contained within amino acids 173–192; 
nonetheless, a number of mutations within this region of EC2 
(P176S, I182F, N184Y and F186S) had no effect on mAb bind-
ing (Figure 1A), suggesting that these are not contact residues for 
these mAbs.
Our principal motivation for generating anti-CD81 mAbs is to 
study HCV entry; we tested all of the EC2 mAbs for anti-HCV 
activity and observed a ~500-fold range in potency (Figure 2). 
Our current understanding of HCV-CD81 interactions (based on 
mutagenesis and structural data), suggests that E2 glycoprotein 
binds helix D of the EC2. This directly overlaps with the appar-
ent target of group I mAbs and we reasoned that these mAbs 
may exhibit greater anti-HCV activity. However, we failed to 
observe any correlation between epitope specificity and anti-HCV 
potency (Figure 2). This may indicate that the binding of any anti-
body to the EC2 is likely to prevent E2 binding; this is not unrea-
sonable given the EC2 has a compact structure, measuring 3nm at 
its widest point, whereas an antibody is a bulky molecule, measur-
ing ~15nm by 10nm. However, one of the group II mAbs (1s73) 
displayed negligible anti-HCV activity (Figure 1), suggesting that 
antibody binding per se is not sufficient to prevent infection.
To further investigate the determinants of anti-HCV potency, we 
evaluated the binding of each mAb to CD81 expressed in a vari-
ety of contexts. We found little or no correlation between neutral-
izing activity and antibody binding to yeast-derived recombinant 
CD81 (either detergent-purified or presented on the membrane 
surface of P. pastoris protoplasts); in contrast, antibody binding 
to CD81 on the surface of human hepatoma cells was an excel-
lent predictor of anti-viral potency (Figure 3). These data suggest 
that expression of CD81 in more physiologically relevant mem-
brane environments may alter EC2 presentation and/or conforma-
tion and reveal differences in mAb binding that are not apparent in 
in vitro plate based assays. Moreover, the degree of antibody 
binding to CD81 presented in physiological settings determines 
anti-HCV potency.
We have not investigated the potential compositional or biochemi-
cal differences between yeast and mammalian membranes that 
may influence CD81 presentation; however, there are at least two 
important features that should be considered. The interactions 
between CD81 and its various molecular partners (e.g. CD9, CD19, 
CD3) are poorly understood; nonetheless, it is likely that het-
erotypic interactions occurring in the plasma membrane of mam-
malian cells alters CD81 epitope availability and modulate mAb 
binding. Although tetraspanins are found in all higher eukaryotes 
they are completely absent from yeast53, consequently, CD81 will 
not have any natural binding partners in P. pastoris and this may 
impact epitope presentation. Furthermore, one interpretation of the 
recent crystal structure of CD81 might be that cholesterol, resident 
in the plasma membrane of mammalian cells, may regulate CD81 
EC2 conformation15. Unlike mammalian cells, the principal sterol 
in yeast membranes is ergosterol54, and conformational switching 
may not occur in this setting. Whether these mAbs can differentiate 
between ‘open’ and ‘closed’ conformers of CD81 is a focus of on-
going investigations.
Finally, we used two mAbs as tools to study the molecular 
distribution of CD81. Immunogold labelling of cell-surface 
endogenous CD81, combined with spatial statistics analysis, 
identified at least two populations of CD81 with distinct distribu-
tions: monodispersed CD81 with little spatial organisation and 
clustered CD81 found in higher-order assemblies, possibly rep-
resenting tetraspanin-enriched microdomains1–3. This data may 
be consistent with the notion of a dynamic equilibrium of CD81 
transitioning from monomeric to oligomeric forms. Notably, the 
two mAbs appeared to differ in their ability to recognise these 
distinct states of CD81: 2s20 labelling revealed both clustered 
and monodispersed CD81, whereas large clusters of CD81 were 
not apparent on 1s337-labelled cells. Further studies will be nec-
essary to understand the relevance of these different distributions 
of CD81.
Here, we present a panel of epitope-mapped and validated anti-
CD81 mAbs that have immediate relevance to the study of HCV 
entry. Moreover, we believe they may provide useful tools for 
investigating the basic biology of CD81 and tetraspanins in general. 
The ability to study CD81 distribution in situ, and to discriminate 
different membrane-resident populations, is particularly valuable 
given that tetraspanin function is defined by an ability to spatially 
organise their molecular partners and compartmentalise cellular 
membranes.
Data availability
The data underlying Figure 1–Figure 4 and S1, S2 and further sup-
porting data are provided at the Open Science Framework http://
doi.org/10.17605/OSF.IO/HKN3X55
Animal statement
The immunisation protocol and number of animals required were 
submitted for ethical review by the University of Birmingham Ethi-
cal Review SubCommittee (BERSC) and conducted under Home 
Office licence PPL 40/2220 and PIL 40/2284.
The study design required two female young adult Balb/c mice 
obtained from the Specific Pathogen Free (SPF) breeding unit 
in the University of Birmingham BioMedical Services Unit. The 
initial injection, no more than 100µl sub-cutaneously, as per home 
office guidelines, was combined with Complete Freund’s Adju-
vant, which had been previously shown not to raise inflammatory 
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reactions. Three booster immunisations of 100µl in Phosphate 
Buffered Saline (PBS) were administered intraperitoneally at 
2 week intervals. The animals were monitored within 4h, at the 
end of the working day and twice daily thereafter for any adverse 
reactions. None were apparent. A tail bleed of not more than 
50µl was taken 6 weeks after the primary immunisation and assess- 
ed for a specifc polyclonal response. A chosen mouse was culled,  
in accordance with home offce guidelines, and the spleen sterilely 
The second mouse was culled for a fusion 2  weeks later, having
 
received 1 more booster injection.
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Supplementary material
Supplementary Figure 1: Representative immunostaining with anti-CD81 mAbs. A. Fluorescence intensity histograms for CD81 
labeled Huh-7.5 cells acquired by flow cytometry. Examples of low (1s73), intermediate (2s66) and high affinity mAbs (1s337) are 
provided. The grey histogram represents binding of an irrelevant mouse IgG. All mAbs used at 1µg/ml B. Matched microscopy images 
of immunostained Huh-7 CD81 KO cells with and without lentiviral transduction to add back CD81. Scale bar 200µm.
Click here to access the data.
Supplementary Figure 2: Inhibition of E2-CD81 interactions. The binding of soluble HCV E2 to GST-CD81EC2 in the presence of 
1µg/ml of anti-CD81 mAb was monitored by ELISA. The percent inhibition was calculated by comparison to E2-CD81 interactions 
occurring in the presence of an irrelevant mouse IgG.
Click here to access the data.
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 Stephen Griffin
Faculty of Medicine and Health, St James's University Hospital, University of Leeds, Leeds, UK
Grove and colleagues detail the creation of a panel of anti human CD81 antibodies, which they intended
for use characterising interactions with hepatitis C virus (HCV) during the entry process. The monoclonals
have been well characterised, especially compared with other reagents available commercially, and
encompass reagents specific to both the large extracellular loop and other regions of the protein.
Select reagents were then used as competitors for HCV entry, and to stain CD81 complexes on the
surface of HEK cells. The authors found no correlation between m'ab binding sites and ability to block
HCV entry, but did correlate this with the overall avidity of m'abs for cell expressed CD81. Scanning
immunogold EM conducted upon plasma membranes revealed apparently distinct complexes of CD81,
consistent with its organisation within the tetraspannin web.
Some comments for consideration:
For the HCV entry inhibition experiments, have the authors considered that entry may be blocked
by the m'abs promoting internalisation of the CD81? This may explain the apparent independence
with respect to binding sites.
 
I do not understand the statistical basis for ignoring the outliers in figure 3c. Plus experimental
repeats and tests should be clarified in general.
 
Controls are missing for the SEM studies, such as primary/secondary antibody controls and cells
lacking CD81, such as HepG2.
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I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
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   Peter N. Monk
Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Sheffield, UK
The article discusses the ability of a set of antibodies raised against CD81 expressed in Pichia pastoris to
inhibit hepatitis C virus entry. The antibodies may be useful research tools in further defining the role of
CD81 in viral entry, and the functions of tetraspanins generally. Generally, the experiments have been
performed well, and the article is clearly written. However, there are some points that should be
addressed by the authors:
Antibody inhibition of HCV binding is presumed to be by steric hindrance rather than blockade of
specific binding sites. This could be explored more clearly using fab fragments of the antibodies
that are a fraction of the size of the intact antibodies. Why was this simple and obvious procedure
not performed?
 
The hybridoma supernatants were screened against a recombinant form of the CD81 EC2 fused to
MBP. It is well know that recombinant tetraspanin EC2 proteins contain a proportion of misfolded
protein that could bias the selection of hybridomas. Why was screening not primarily performed
against a cell line expressing native CD81?
 
GST-CD81 EC2 was used for evaluation of HCV E2 binding. Why was this used rather than
MBP-EC2?
 
No competitive binding study was performed. This could have helped define EC2 domains
recognised by the antibodies, particularly if fab fragments were used.
 
In Fig 3c, the authors decide to ignore 2 outliers to perform the linear regression analysis. On what
statistical basis were these 'outliers' defined? What are the biological properties associated with
these antibodies that might make them behve in this way?
 
The selection of antibodies for nanoscale distribution experiments was performed on the basis of
high affinity. A more rational choice for this might have been one high and one low affinity antibody.
Low affinity antibodies have been used by several research groups to discriminate clustered v
unclustered tetraspanins at the cell surface.
 
Although the authors detect apparently different populations of CD81 on HEK cells, it is very
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Although the authors detect apparently different populations of CD81 on HEK cells, it is very
difficult to draw any conclusions from a single type of experiment. Does modulation of cholesterol
or the actin cytoskeleton affect the populations? Does clustering of tetraspanin-associated proteisn
affect distribution? Do the different populations bind EC2 differently?
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This manuscript documents the generation and characterization of novel monoclonal antibodies (mAbs)
specific for tetraspanin CD81. The antibodies were classified in two epitope groups targeting opposing
sides. A wide range of anti-HCV potencies was observed independent of their epitope grouping, but
associated with their relative affinity for cell-surface expressed CD81. In addition, testing the
CD81-antibodies in SEM revealed both monomeric and clustered CD81 molecules.
The manuscript is well-written and the novel CD81-antibodies provide new tools to study CD81 and HCV
binding.
Suggestions for improvement:
It is observed that the group I mAbs (2s20, 2s48, 2s63, 2s66 and 2s131) recognise a region
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 It is observed that the group I mAbs (2s20, 2s48, 2s63, 2s66 and 2s131) recognise a region
centered around helix D of the EC2. In this context and in relation to their SEM data, it is important
to discuss the role of the delta-helix in CD81 dimerisation .
 
The current SEM analyse does not include antibody isotype controls. These should be included to
exclude aspecific signals in SEM analysis.
 
Super-resolution of the tetraspanin web has recently revealed that tetraspanins (including CD81)
preferentially homodimerize . The discussion may benefit from reflecting the current SEM data
with this study.
 
CD81 also interferes with HIV replication. Did the authors also analyse the novel CD81-antibodies
in respect to blocking HIV antigen binding or replication? This should at least be discussed.
 
It is unclear why the 1s337 antibody only recognizes mononeric CD81. Can the authors speculate
what the underlying mechanism is? Is it interference with a CD81-partner binding?
 
Include statistics, in particular how many times experiments have been performed.
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